| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | NEUTRAL | BUY | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 5.20▼ | 5.17▼ | 5.20▼ | 5.13▲ | 4.69▲ |
| MA10 | 5.19▼ | 5.22▼ | 5.23▼ | 5.00▲ | 5.27▼ |
| MA20 | 5.17▼ | 5.21▼ | 5.18▼ | 4.63▲ | 6.13▼ |
| MA50 | 5.21▼ | 5.13▲ | 5.10▲ | 5.30▼ | 6.70▼ |
| MA100 | 5.22▼ | 5.07▲ | 4.82▲ | 6.33▼ | 6.31▼ |
| MA200 | 5.17▼ | 4.76▲ | 4.86▲ | 6.66▼ | 8.23▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.005▲ | -0.014▼ | -0.009▼ | 0.125▲ | -0.139▼ |
| RSI | 41.544▼ | 47.995▼ | 51.110▲ | 54.170▲ | 40.641▼ |
| STOCH | 79.156 | 26.188 | 49.511 | 86.558▲ | 27.160 |
| WILL %R | -81.250▼ | -75.472▼ | -51.948 | -15.663▲ | -55.356 |
| CCI | 22.525 | -65.326 | -2.580 | 88.883 | -45.408 |
|
Thursday, May 01, 2025 04:45 AM
Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing next-generation peptide-based therapeutics for liver and cardiometabolic diseases, today announced that the ...
|
|
Wednesday, April 30, 2025 11:37 PM
Tokyo Stock Exchange-listed Alt is under investigation for overstating sales of its main product, an AI transcription service.
|
|
Wednesday, April 30, 2025 01:50 AM
The market for obesity drugs presents one of the most lucrative targets for biopharmaceutical companies. Eli Lilly and Novo Nordisk are already raking in billions of dollars in sales with their weight ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 01/05/25 | 5.25 | 5.365 | 5.0748 | 5.17 | 2,094,707 |
| 30/04/25 | 5.01 | 5.2952 | 4.98 | 5.25 | 1,804,924 |
| 29/04/25 | 5.02 | 5.21 | 4.98 | 5.09 | 1,475,930 |
| 28/04/25 | 5.08 | 5.23 | 4.93 | 5.06 | 1,770,366 |
| 25/04/25 | 5.12 | 5.21 | 5.01 | 5.07 | 1,025,164 |
| 24/04/25 | 4.97 | 5.175 | 4.92 | 5.17 | 1,474,332 |
| 23/04/25 | 5.00 | 5.225 | 4.95 | 4.97 | 1,723,683 |
| 22/04/25 | 4.88 | 4.938 | 4.71 | 4.85 | 1,814,311 |
| 21/04/25 | 4.43 | 4.8875 | 4.37 | 4.79 | 2,221,181 |
| 17/04/25 | 4.41 | 4.62 | 4.37 | 4.55 | 2,101,826 |
|
|
||||
|
|
||||
|
|